Cat. #152045
Anti-TACE [D1(A12)] rAb
Cat. #: 152045
Sub-type: Primary antibody
Unit size: 100 ug
Target: TACE (ADAM17)
Class: Recombinant
Application: Fn
Reactivity: Human
Host: Human
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christopher Tape ; Gillian Murphy
Institute: Cancer Research UK, Cambridge Institute, England
Primary Citation: Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-TACE [D1(A12)] rAb
- Alternate name: Anti-TACE [D1(A12)]
- Clone: D1 (A12)
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Biotin
- Molecular weight: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated
- Reactivity: Human
- Host: Human
- Application: Fn
- Description: Anti-TACE [D1 (A12)] is a human recombinant antibody. This antibody displays inhibitory behaviour to TNF-alpha converting enzyme (TACE). TACE is a membrane-bound metalloprotease (ADAM17) proved capable of cleaving a variety of pathologically significant substrates. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. D1(A12) binds a cross-domain epitope. D1(A12) is the first ADAM inhibitor to show an affinity preference for the complete TACE ectodomain over the isolated catalytic domain. This antibody is a selective TACE antagonist and provides a unique alternative to small molecule metalloprotease inhibition. This antibody allows the study of the individual pathological impact of TACE activity.
- Immunogen: Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.
- Isotype: IgG1
- Recommended controls: Brain, heart, kidney, liver, lung and spleen
Target Details
- Target: TACE (ADAM17)
- Molecular weight: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated
- Tissue cell line specificity: Brain, heart, kidney, liver, lung and spleen
- Target background: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule meta...
Applications
- Application: Fn
Handling
- Format: Liquid
- Concentration: 5.9 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-TACE, Recombinant [D1 (A12)] (mouse IgG)
References
- Caiazza et al. 2015. Br J Cancer. 112(12):1895-1903. PMID: 26010411.
- Issuree et al. 2013. J Clin Invest. 123(2):928-932. PMID: 23348744.
- Richards et al. 2012. PLoS One. 7(7):e40597. PMID: 22792380.
- Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.
